Material Agreements - Additional Information (Detail) $ / shares in Units, $ in Thousands			1 Months Ended					12 Months Ended
	Nov. 03, 2021 shares	Oct. 18, 2021 $ / shares shares	May 31, 2021 USD ($)	Mar. 31, 2021 USD ($) tranche shares	Dec. 31, 2020 USD ($)	Aug. 31, 2020 USD ($) shares	Oct. 31, 2019 USD ($) tranche shares	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Oct. 12, 2021 shares	Nov. 30, 2020 USD ($)	Dec. 31, 2019 USD ($)
License And Other Related Agreements [Line Items]
Class of warrants or rights number of securities covered by the warrants or rights (in shares) | shares				125,000		170,000
Number of tranches | tranche				3			3
Warrants issued during period (in shares) | shares				3
Payment of milestone amount								$ 0	$ 35,000
Restricted cash, non-current					$ 0			20,000	0
Tarsus Warrants
License And Other Related Agreements [Line Items]
Number of securities called by each warrant or right (in shares) | shares		156,746
Navire | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Payment towards upfront amount in connection with license agreement						$ 8,000
Payment towards development amount in connection with license agreement								8,500
Navire | Maximum | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Tiered royalty as a percentage of net sales						15.00%
Navire | Minimum | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Tiered royalty as a percentage of net sales						5.00%
Navire | Specified Development Regulatory Milestone | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount						$ 24,500
Navire | Sales Based Milestone | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Asset acquisition, net sales milestone						357,600
QED | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Payment towards upfront amount in connection with license agreement							$ 10,000
QED | Payable To Related Party Current | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Reimburement amount due towards costs incurred for the study												$ 2,800
QED | Specified Development Regulatory Milestone | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount							7,000
QED | Sales Based Milestone | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Asset acquisition, net sales milestone							87,500
QED | Lian Oncology | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Warrants and rights outstanding value							$ 1,000
Class of warrants or rights expiry period							10 years
QED | Lian Oncology | Tranche One | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Warrants or rights issuable as a percentage of fully diluted equity							10.00%
QED | Lian Oncology | Tranche Two | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Warrants or rights issuable as a percentage of fully diluted equity							10.00%
QED | Lian Oncology | Tranche Three | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Warrants or rights issuable as a percentage of fully diluted equity							10.00%
QED | Lian Oncology | Warrants To Purchase Common Stock | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Class of warrants or rights number of securities covered by the warrants or rights (in shares) | shares		347,569					100,000
Class of warrants or rights exercise price (in dollars per share) | $ / shares		$ 0.000017100448
Myokardia
License And Other Related Agreements [Line Items]
Payment towards upfront amount in connection with license agreement						40,000
Myokardia | Specified Development Regulatory Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount						60,000
Myokardia | Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, net sales milestone						87,500
Myokardia | Non Refundable Financing Milestone Payment
License And Other Related Agreements [Line Items]
Milestone payment payable						35,000
Imputed interest on milestone payment						$ 2,300
Myokardia | Non Refundable Financing Milestone Payment | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Payment of milestone amount					35,000
Myokardia | Warrants To Purchase Common Stock
License And Other Related Agreements [Line Items]
Class of warrants or rights number of securities covered by the warrants or rights (in shares) | shares						170,000				170,000
Warrants and rights outstanding value						$ 33,800
Warrants or rights issuable as a percentage of fully diluted equity						17.00%
Pfizer
License And Other Related Agreements [Line Items]
Commitment to contribute capital											$ 70,000
Upfront payment receivable											$ 20,000
Accounts and other receivables, net, current					20,000				20,000
Restricted cash, non-current					$ 20,000				$ 20,000
Reviral
License And Other Related Agreements [Line Items]
Payment towards upfront amount in connection with license agreement				$ 14,000
Reviral | Specified Development Regulatory Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount				45,000
Reviral | Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, net sales milestone				60,000
Reviral | Specified Development Regulatory And Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount				105,000
Tarsus Pharmaceuticals
License And Other Related Agreements [Line Items]
Payment towards upfront amount in connection with license agreement				15,000
Payment of milestone amount								$ 30,000
Tarsus Pharmaceuticals | Milestone Stage Two
License And Other Related Agreements [Line Items]
Milestone payment payable				10,000
Tarsus Pharmaceuticals | Specified Development Regulatory Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount				75,000
Tarsus Pharmaceuticals | Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, net sales milestone				100,000
Tarsus Pharmaceuticals | Specified Development Regulatory And Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount				$ 175,000
Tarsus Pharmaceuticals | Warrants To Purchase Common Stock
License And Other Related Agreements [Line Items]
Class of warrants or rights number of securities covered by the warrants or rights (in shares) | shares				125,000
Warrants and rights outstanding value				$ 9,400
Class of warrants or rights expiry period				10 years
Class of warrants or rights exercise price (in dollars per share) | $ / shares		$ 0.000017100448
Warrants issued during period (in shares) | shares		2		3
Issuance of ordinary shares upon initial public offering, net of issuance costs (in shares) | shares	78,373
Tarsus Pharmaceuticals | Warrants To Purchase Common Stock | Tranche One
License And Other Related Agreements [Line Items]
Warrants or rights issuable as a percentage of fully diluted equity				12.50%
Tarsus Pharmaceuticals | Warrants To Purchase Common Stock | Tranche Two
License And Other Related Agreements [Line Items]
Warrants or rights issuable as a percentage of fully diluted equity				12.50%
Tarsus Pharmaceuticals | Warrants To Purchase Common Stock | Tranche Three
License And Other Related Agreements [Line Items]
Warrants or rights issuable as a percentage of fully diluted equity				12.50%
Landos
License And Other Related Agreements [Line Items]
Payment towards upfront amount in connection with license agreement			$ 18,000
Landos | Specified Development Regulatory Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount			95,000
Landos | Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, net sales milestone			105,000
Landos | Specified Development Regulatory And Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount			200,000
Nanobiotix
License And Other Related Agreements [Line Items]
Payment towards upfront amount in connection with license agreement			$ 20,000
Nanobiotix | Maximum
License And Other Related Agreements [Line Items]
Tiered royalty as a percentage of net sales			13.00%
Nanobiotix | Minimum
License And Other Related Agreements [Line Items]
Tiered royalty as a percentage of net sales			10.00%
Nanobiotix | Specified Development Regulatory Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount			$ 65,000
Nanobiotix | Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, net sales milestone			155,000
Nanobiotix | Specified Development Regulatory And Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount			220,000
Lyra
License And Other Related Agreements [Line Items]
Payment towards upfront amount in connection with license agreement			12,000
Lyra | Specified Development Regulatory Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount			40,000
Lyra | Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, net sales milestone			95,000
Lyra | Specified Development Regulatory And Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount			$ 135,000